title: Transarterial chemoembolization using docetaxel-loaded phytantriol cubic phase precursor for the treatment of hepatocellular carcinoma.
abstract: The purpose of this study was to evaluate the transarterial chemoembolic agent based on docetaxel-loaded phytantriol cubic phase precursor (DTX PCPP) by in vitro cytotoxicity study and in vivo evaluation of antitumor efficacy as well as the histological examination. The methythiazolyl tereazolium bromide assay in Hep G2 cell line revealed that DTX PCPP generated high cytotoxicity by causing cell apoptosis and G2/M phase arrest. In vivo studies conducted in rabbits bearing VX2 tumors, which were treated with DTX PCPP, used as a transarterial chemoembolic agent, showed a significant antitumor efficacy and prominent higher DTX concentrations in tumor and liver than those in other organs. The histology presented typical necrosis in tumor that demonstrated excellent therapeutic effect. In conclusion, the DTX PCPP could achieve an excellent antitumor effect with low systemic toxicity for the treatment of hepatocellular carcinoma and therefore implied the prospect of DTX PCPP for clinical applications.
authors.affiliation: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Han
authors.forename: Zhouhua
authors.initials: Z
authors.lastname: Wang
authors.forename: Xinsheng
authors.initials: X
authors.lastname: Peng
authors.forename: Bao
authors.initials: B
authors.lastname: Chen
authors.forename: Xinguo
authors.initials: X
authors.lastname: Wen
authors.forename: Yixuan
authors.initials: Y
authors.lastname: Dong
authors.forename: Chuanbin
authors.initials: C
authors.lastname: Wu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003692:Delayed-Action Preparations; D000077143:Docetaxel; D004339:Drug Compounding; D005233:Fatty Alcohols / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005434:Flow Cytometry; D056945:Hep G2 Cells; D006499:Hepatic Artery; D006801:Humans; D020100:Hydrogels; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011817:Rabbits; D012995:Solubility; D043823:Taxoids / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution; D014783:Viscosity; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D005233:Fatty Alcohols; D020100:Hydrogels; D011355:Prodrugs; D043823:Taxoids; D000077143:Docetaxel; C508873:3,7,11,15-tetramethyl-1,2,3-hexadecanetriol